ProMIS Neurosciences (PMN)
NASDAQ:PMN
Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$22.36M
Enterprise Value-$50.23M
Total Cash (Recent Filing)$63.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 17, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-2.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.22
Forecast
1Y Price Target
$35.00Price Target Upside331.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure and a meaningful equity base reduce financial risk and increase strategic flexibility. For a clinical-stage biotech, this lowers near-term insolvency risk and gives management room to prioritize R&D and trial completion without immediate pressure to service borrowings.
Clear Clinical Path For Lead AssetHaving defined, near-to-intermediate clinical milestones for PMN310 creates a structural roadmap for value creation. Execution on existing trials concentrates R&D efforts, clarifies regulatory pathways, and can materially de-risk the program if clinical and biomarker outcomes support the drug's selective targeting approach.
Strengthened Cash Runway Via FinancingA sizable financing commitment plus current cash gives management the runway to complete planned clinical activities without imminent capital raises. This structural liquidity reduces near-term dilution risk and enables focused execution on pivotal trial endpoints across the next 12–18 months.
Bears Say
Pre-revenue With Large LossesBeing pre-revenue with sustained multi-year net losses means the company's long-term viability depends on R&D success or continued external funding. Persistent operating deficits create recurring financing needs and make strategic outcomes (trial success or partnerships) determinative for future cash flows.
Consistent Negative Cash FlowMaterial and persistent negative operating and free cash flow indicate the company is structurally cash consumptive. This necessitates ongoing capital markets access or partnerships, increasing dilution risk and making long-term program continuation contingent on securing new financing or milestone-linked deals.
Inconsistent Equity And Weak ReturnsHistorical swings into negative equity and persistently negative ROE reflect prior capital shortfalls and limited ability to generate shareholder returns. This structural variability signals recurring recapitalizations and heightens investor risk if clinical outcomes do not materialize into commercial or partnering value.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $22.36M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Aug 17, 2026 which is in 91 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on May 12, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.06 by -$0.2.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.41.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.06. Following the earnings report the stock price went down -1.779%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
PMN Stock 12 Month Forecast
Average Price Target
$35.00
▲(331.03% Upside)